Genomics firm The DNA Company acquires My Pain Sensei for $30 million
Category: #healthcare  By Akshay Kedari  Date: 2020-05-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Genomics firm The DNA Company acquires My Pain Sensei for $30 million

The DNA Company, a renowned functional genomics provider, has reportedly announced that it has acquired MPS (My Pain Sensei), an AI-based digital therapeutics app, for a total amount of about $30M, forming My Next Health. The newly acquired MPS provides My Next Health an AI-based platform to build multiple health applications.

As the newly formed My Next Health, the firm would focus on utilizing digital therapeutics and precision medicine to build health management applications based on genomics and provide patients with genetic information tailored for their unique biology. This acquisition also provides Health Canada’s Class 1 Medical Device Establishment License to My Next Health for applications that are related to the coronavirus and chronic pain.

The MPS platform of My Next Health, which integrates genomic insights and big data with tracking tools and conversational AI, was created by MPS in collaboration with the renowned technology company, IBM, and comprises access to over 60 million electronic medical records and insights from 32 billion claims.

This info further enables the platform to identify important insights regarding identifiable symptoms, chronic pain treatment efficacy, diagnoses, and other chronic conditions. The company’s My Next Health apps make those tools, insights, as well as interventions accessible to healthcare providers and patients. My Next Health is developing a special COVID-19 application, as its first app. The application would assesses a user’s risk profile which could lead to the user developing complications due to the virus.

My Next Health CEO, Kashif Khan stated that the coronavirus pandemic has shown how a virus can easily damage the global healthcare system at a mere moment’s notice. 

Khan further added that new advances in the functional genomics are likely to enable humanity to better understand the biological weaknesses that are exploited by this novel virus. This information could help leverage present treatment options to enhance patient results and decrease the substantial load being exerted on the global healthcare system. The MPS acquisition would help the company fight these as well as other issues.

 

Source credit: https://hitconsultant.net/2020/05/13/the-dna-company-acquires-ai-digital-therapeutics-app/#.Xrw07UQzbIU

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Syros unveils Phase 1 clinical trial data of SY-5609; cohort expanded
Syros unveils Phase 1 clinical trial data of SY-5609; cohort expanded
By Akshay Kedari

Syros Pharmaceuticals has announced initial safety, pharmacodynamics (PD) and pharmacokinetics (PK) ...

Ezra gets US FDA clearance to use AI for examining prostate MRIs
Ezra gets US FDA clearance to use AI for examining prostate MRIs
By Akshay Kedari

Ezra is a U.S-based startup developing a cancer screening platform that uses a combination of A...

HOPCo acquires Stryker’s health system orthopedic service operations
HOPCo acquires Stryker’s health system orthopedic service operations
By Akshay Kedari

Healthcare Outcomes Performance Company (HOPCo), a leading provider of musculoskeletal value-based h...